DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML

Abroad (travel likely)RecruitingPHASE3

Conditions

AML (Acute Myeloid Leukemia)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
Contact: Study coordinator (Zeping Zhou) · zhouzeping@kmmu.edu.cn · +86 187 8857 1605
Zhou · zhouzeping@kmmu.edu.cn

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE3

Feldkirch, Austria · Salzburg, Austria

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Acute Myeloid Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm · Acute Myeloid Leukemia Post Cytotoxic Therapy

Abroad (travel likely)RecruitingPHASE2

Birmingham, United States · Phoenix, United States

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia

Abroad (travel likely)RecruitingPHASE2

Duarte, United States

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE2

Tucson, United States · Tucson, United States